Inhibitors of bromodomain and extra-terminal motif (BET)
proteins are emerging epigenetic
therapeutics that suppress gene expressions that drive
cancer and
inflammation. The present study examined anti-inflammatory effects of a
quinazoline-based BET inhibitor, CN210, in a murine
ileitis model. CN210 was given orally 30 min before and 24 h after a subcutaneous administration of
indomethacin. Macroscopic and histological evidences of
ileitis, mucosal
myeloperoxidase (MPO) activity and
cytokine expressions were evaluated 48 h after the
indomethacin administration. To further characterize the anti-inflammatory pathways modulated by CN210, its effects on RAW264 cells treated with
lipopolysaccharide (LPS) were investigated. Competitive
ligand binding and docking studies of CN210 to
CREB-binding protein (CBP) and p300 were also performed.
Oral administration of CN210 significantly reduced the severity of
ileitis, normalized both proinflammatory MPO activity and concomitant
cytokine expressions induced by
indomethacin administration. Furthermore, CN210 attenuated the expression of
cytokines and reversed the activation of nuclear factor κB (NF-κB) and
mitogen-activated protein kinases (MAPK) induced by LPS. Competitive
ligand binding assays showed that CN210 bound to the bromodomains of two paralogous
histone acetyltransferases, CBP and p300, in addition to the bromodomains of BET
proteins. Docking studies of CN210 to the bromodomains of CBP and p300 showed a similarity to the binding mode of SGC-CBP30, a specific CBP/p300 inhibitor. CN210 ameliorates
indomethacin-induced
ileitis by inhibiting the expression of inflammatory
cytokines through the attenuation of NF-κB and MAPK pathways. CN210 thus represents a new mode of
therapy for non-steroidal anti-inflammatory
drug-induced
ileitis and
inflammatory bowel disease.